Applied Therapeutics Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic Cardiomyopathy
AT-001 (caficrestat) demonstrated a strong trend in stabilizing cardiac functional capacity, while the placebo group declined over 15 months
Related news for (APLT)
- Breaking News: MoBot’s Latest Update as of 10/02/25 01:00 PM
- MoBot’s Stock Market Highlights – 10/01/25 10:00 AM
- Today’s Top Performers: MoBot’s Market Review 09/26/25 03:00 PM
- MoBot alert highlights: NASDAQ: APLT, NASDAQ: APDN, NASDAQ: AQMS, NASDAQ: AUID, NASDAQ: OVID (09/26/25 02:00 PM)
- MoBot’s Stock Market Highlights – 09/26/25 01:00 PM